Bright Uro, a medical device company to transform care for lower urinary tract symptoms (LUTS) through innovations in urodynamics, announced today the second closing of its Series A funding round, which was oversubscribed by nearly 40% above and secured a total of $32 million for the company.
Laborie Medical Technologies (Laborie), a leading global provider of urology diagnostic and therapeutic solutions, remains the lead investor, and it is now being joined by the University of California (via UC Investments), Freepoint Capital Group, and Laurelin Investors.
The additional funding will support Bright Uro’s anticipated launch of its Glean Urodynamics System in 2025, as well as manufacturing capacity expansion and R&D activities to expand the future pipeline.
KEY QUOTES:
“The Glean system has the potential to significantly impact the urodynamics landscape, and we remain very supportive of the Bright Uro team. This funding round will help enable improved patient and clinician access to the technology which directly aligns with Laborie’s mission of preserving and restoring human dignity.”
- Michael Frazzette, President and CEO of Laborie
“The overwhelming interest from a diverse range of sophisticated investors is a true testament to the compelling mission we are on. With this funding, we are well resourced for the launch of Glean in 2025, while also continuing to resource our pipeline of innovation. We have never been more confident in the expected impact Glean will have for clinicians and millions of patients suffering from urinary issues.”
- Derek Herrera, founder and CEO of Bright Uro
